🔥🐔 BizChicken 🐔🔥

Companies Similar to Prelude Therapeutics Incorporated

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Probody technology platform

Cytom X Therapeutics, Inc. is an oncology-focused biopharmaceutical company that develops antibody therapeutics based on its Probody technology platform for treating cancer. Its product candidates include CX-2009, CX-2029, BMS-986249, BMS-986288, CX-2043, and CX-904, targeting various cancers and currently in clinical trials.

Tags: antibody therapeutics, biopharmaceuticals, cancer treatment, clinical trials, oncology

Symbol: CTMX

Recent Price: $1.02

Industry: Biotechnology

CEO: Dr. Sean A. McCarthy DPHIL

Sector: Healthcare

Employees: 120

Address: 151 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 515 3185

Last updated: 2024-12-31

Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated logo
Market Cap: Low
Employees: Low

PRT543

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focusing on novel precision cancer medicines, including products like PRT543, PRT811, PRT1419, PRT2527, and others at various stages of development or trials.

Tags: biotechnology, cancer, clinical trials, oncology, precision medicine

Symbol: PRLD

Recent Price: $1.21

Industry: Biotechnology

CEO: Dr. Krishna Vaddi D.V.M., Ph.D.

Sector: Healthcare

Employees: 128

Address: 200 Powder Mill Road, Wilmington, DE 19803

Phone: 302 467 1280

Leadership

  • Kris Vaddi, Ph.D., Chief Executive Officer
  • Jane Huang, M.D., President and Chief Medical Officer
  • Bryant Lim, Chief Legal Officer, Corporate Secretary & Interim Chief Financial Officer
  • Andrew Combs, Ph.D., Chief Chemistry Officer
  • Peggy Scherle, Ph.D., Chief Scientific Officer
  • Michele Porreca, M.B.A., Chief People Officer
  • Sean Brusky, M.B.A., Chief Business Officer
  • Naveen Babbar, Ph.D., Senior Vice President, Translation Medicine
  • Aimee Crombie, Ph.D., SVP & Head of Strategic Planning & Operations
  • Robert Doody, Senior Vice President, Investor Relations
  • Wan-Jen Hong, M.D., Senior Vice President, Clinical Development
  • Bill Novotny, M.D., Senior Vice President, Clinical Development
  • Madhu Pudipeddi, Ph.D., Senior Vice President, Technical Operations
  • Paul A. Friedman, M.D., Chair
  • David Bonita, M.D., Director
  • Julian C. Baker, Director
  • Mardi C. Dier, Director
  • Victor Sandor, M.D., Director
  • Martin Babler, Director

Last updated: 2024-12-31

Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. logo
Market Cap: High
Employees: Low

rusfertide (PTG-300), PN-943, PN-235

Protagonist Therapeutics, Inc. is a biopharmaceutical company that focuses on the discovery and development of peptide-based therapeutic drugs for hematology, blood disorders, and inflammatory and immunomodulatory diseases.

Tags: biopharmaceutical, blood disorders, hematology, immunomodulatory diseases, inflammatory diseases, peptide-based drugs

Symbol: PTGX

Recent Price: $38.51

Industry: Biotechnology

CEO: Dr. Dinesh V. Patel Ph.D.

Sector: Healthcare

Employees: 125

Address: 7707 Gateway Boulevard, Newark, CA 94560-1160

Phone: 510 474 0170

Last updated: 2024-12-31

Pyxis Oncology, Inc.

Pyxis Oncology, Inc. logo
Market Cap: Low
Employees: Lowest

PYX-106, PYX-102, PYX-201, PYX-202, PYX-203

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, focuses on developing therapies to treat various cancers through immune-oncology and antibody drug conjugate product candidates.

Tags: antibody drug conjugate, biopharmaceutical, cancer therapy, immune-oncology, solid tumors

Symbol: PYXS

Recent Price: $1.56

Industry: Biotechnology

CEO: Dr. Lara S. Sullivan M.D., MBA

Sector: Healthcare

Employees: 55

Address: 35 Cambridgepark Drive, Cambridge, MA 02140

Phone: 617 221 9059

Last updated: 2024-12-31

Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

Acrivon Predictive Precision Proteomics

Acrivon Therapeutics is a clinical stage biopharmaceutical company developing oncology medicines using a proteomics-based platform to identify patient responders. Their lead candidate, ACR-368, is in Phase 2 trials for various cancers.

Tags: ACR-368, CHK1, CHK2, biopharmaceutical, clinical trials, oncology, precision medicine, proteomics

Symbol: ACRV

Recent Price: $5.41

Industry: Biotechnology

CEO: Dr. Peter Blume-Jensen M.D., Ph.D.

Sector: Healthcare

Employees: 58

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 617-207-8979

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

VAL-083, REM-001

Kintara Therapeutics is a clinical stage drug development company focused on developing and commercializing anti-cancer therapies for drug-resistant solid tumors.

Tags: REM-001, VAL-083, anti-cancer therapies, clinical stage, drug development

Symbol: KTRA

Recent Price: $0.22

Industry: Biotechnology

CEO: Mr. Jeffrey A. Bacha B.Sc., M.B.A.

Sector: Healthcare

Employees: 1

Address: 12707 High Bluff Drive, San Diego, CA 92130

Phone: 858 350 4364

Leadership

  • Robert E. Hoffman, President, CEO, CFO and Chairman of the Board
  • Greg A. Johnson, (Acting) Head of Operations
  • Laura Johnson, Director
  • Tamara A. Favorito, Director
  • Robert J. Toth, Jr., M.B.A., Director

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

PDS Biotechnology Corporation

PDS Biotechnology Corporation logo
Market Cap: Low
Employees: Lowest

PDS0101

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101, is in Phase II clinical trial for treating various human papillomavirus-associated malignancies.

Tags: biopharmaceutical, cancer immunotherapies, clinical trials, clinical-stage, oncology, vaccines

Symbol: PDSB

Recent Price: $1.69

Industry: Biotechnology

CEO: Dr. Frank K. Bedu-Addo Ph.D.

Sector: Healthcare

Employees: 25

Address: 25B Vreeland Road, Florham Park, NJ 07932

Phone: 800 208 3343

Leadership

  • Frank Bedu-Addo, Ph.D., Chief Executive Officer, Director
  • Stephan Toutain, Chief Operating Officer
  • Lars Boesgaard, Chief Financial Officer
  • Gregory Conn, Ph.D., Chief Scientific Officer
  • Kirk Shepard, M.D., Chief Medical Officer
  • Spencer Brown, Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer
  • Rory Cullinane, Vice President of Quality
  • Joe Dervan, Ph.D., Vice President of Research and Development
  • David Schaaf, M.D., Vice President of Medical Affairs
  • Sir Richard Sykes, Director
  • Ilian Iliev, Ph.D., Director
  • Gregory Freitag, J.D., CPA, Director
  • Otis W. Brawley, M.D., Director
  • Kamil Ali-Jackson, J.D., Director
  • Stephen Glover, Chairman

Last updated: 2024-12-31

Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

PLN-74809

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of fibrosis and related diseases. Their lead product candidate, PLN-74809, is currently in Phase 2a trials.

Tags: biopharmaceutical, clinical trials, fibrosis, integrin inhibitor, therapies

Symbol: PLRX

Recent Price: $12.79

Industry: Biotechnology

CEO: Dr. Bernard Coulie M.B.A., M.D., Ph.D.

Sector: Healthcare

Employees: 166

Address: 260 Littlefield Avenue, South San Francisco, CA 94080

Phone: 650 481 6770

Last updated: 2024-12-31

PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

PC14586

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule and tumor-agnostic therapies targeting p53 mutations in cancer, including lead product candidate PC14586.

Tags: Biotechnology, Cancer Therapies, Precision Oncology, Small Molecules, p53 Mutations

Symbol: PMVP

Recent Price: $1.49

Industry: Biotechnology

CEO: Dr. David H. Mack Ph.D.

Sector: Healthcare

Employees: 63

Address: 8 Clarke Drive, Cranbury, NJ 08512

Phone: 609 642 6670

Last updated: 2024-12-31

Predictive Oncology Inc.

Predictive Oncology Inc. logo
Market Cap: Lowest
Employees: Lowest

Personalized Cancer Therapies

Predictive Oncology Inc. is a knowledge-driven company focusing on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States, operating in four segments: Helomics, z PREDICTA, Soluble, and Skyline.

Tags: Artificial Intelligence, Cancer Therapies, Clinical Testing, Disease Models, Drug Discovery, Genomic Profiling, High-Throughput Chromatography

Symbol: POAI

Recent Price: $0.90

Industry: Medical - Instruments & Supplies

CEO: Mr. Raymond F. Vennare

Sector: Healthcare

Employees: 34

Address: 2915 Commers Drive, Eagan, MN 55121

Phone: 651 389 4800

Last updated: 2024-12-31

PureTech Health plc

PureTech Health plc logo
Market Cap: Medium
Employees: Low

Kar XT

Pure Tech Health plc is a clinical-stage biotherapeutics company focused on the discovery, development, and commercialization of medicines for a range of diseases including inflammatory, fibrotic, immunological, and neurological conditions.

Tags: Kar XT, biotherapeutics, clinical stage, fibrotic diseases, immunological diseases, inflammatory diseases, medicines, neurological diseases

Symbol: PRTC

Recent Price: $18.98

Industry: Biotechnology

CEO: Dr. Bharatt M. Chowrira J.D., Ph.D.

Sector: Healthcare

Employees: 90

Address: 6 Tide Street, Boston, MA 02210

Phone: 617 482 2333

Last updated: 2024-12-31

PTC Therapeutics, Inc.

PTC Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.

Tags: Duchenne muscular dystrophy, biopharmaceutical, medicine development, rare disorders, spinal muscular atrophy

Symbol: PTCT

Recent Price: $45.77

Industry: Biotechnology

CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.

Sector: Healthcare

Employees: 988

Address: 100 Corporate Court, South Plainfield, NJ 07080

Phone: 908 222 7000

Leadership

  • Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
  • Neil Almstead, Ph.D., Chief Technical Operations Officer
  • John Baird, Ph.D., Chief of Staff to the CEO
  • Mark E. Boulding, Executive Vice President and Chief Legal Officer
  • Lee Golden, M.D., Chief Medical Officer
  • Pierre Gravier, Chief Financial Officer
  • Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
  • Linda Montella-Carter, Senior Vice President and Chief Information Officer
  • Eric Pauwels, Chief Business Officer
  • Hege Sollie-Zetlmayer, Chief Human Resources Officer
  • Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
  • Michael Schmertzler, Chairman
  • William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
  • Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
  • Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
  • Emma Reeve, Independent Board Director
  • Mary Smith, The VENG Group
  • David P. Southwell, Former CEO, TScan Therapeutics
  • Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
  • Alethia Young, Chief Financial Officer, Bicycle Therapeutics
  • Jerome B. Zeldis, M.D., Ph.D., Independent Board Director

Last updated: 2024-12-31

Protagenic Therapeutics, Inc.

Protagenic Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

PT00114

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, aims to regulate stress response and restore healthy brain function.

Tags: biopharmaceutical, brain health, mood disorders, neuropsychiatric disorders, stress response, therapeutics

Symbol: PTIX

Recent Price: $0.54

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 1

Address: 149 Fifth Avenue, New York, NY 10010

Phone: 212 994 8200

Last updated: 2024-12-31

RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

RPT193, FLX475

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapies targeting oncology and inflammatory diseases. Its leading drug candidates include RPT193 for inflammation and FLX475 for oncology.

Tags: FLX475, RPT193, biopharmaceutical, clinical-stage, immunology, inflammatory diseases, oncology

Symbol: RAPT

Recent Price: $1.62

Industry: Biotechnology

CEO: Dr. Brian Russell Wong M.D., Ph.D.

Sector: Healthcare

Employees: 122

Address: 561 Eccles Avenue, South San Francisco, CA 94080

Phone: 650 489 9000

Last updated: 2024-12-31

Protara Therapeutics, Inc.

Protara Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

N/A

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.

No tags available.

Symbol: TARA

Recent Price: $5.28

Industry: Biotechnology

CEO: Mr. Jesse Shefferman

Sector: Healthcare

Employees: 26

Address: 345 Park Avenue South, New York, NY 10010

Phone: 646 844 0337

Last updated: 2024-12-31

Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TPST-1495, TPST-1120, TREX-1

Tempest Therapeutics Inc. is a clinical-stage oncology company developing small molecule therapeutics to treat cancer, with key programs in TPST-1495 and TPST-1120, and research in TREX-1 enzyme modulation.

Tags: biotechnology, cancer treatment, clinical-stage, drug development, immune response, oncology, small molecule therapeutics

Symbol: TPST

Recent Price: $0.84

Industry: Biotechnology

CEO: Mr. Stephen R. Brady J.D., LLM

Sector: Healthcare

Employees: 17

Address: 7000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 798 8589

Last updated: 2024-12-31

Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. logo
Market Cap: Medium
Employees: Low

PRAX-114, PRAX-944, PRAX-562, PRAX-222, KCNT1 program

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal imbalance, with multiple products in different stages of clinical trials.

Tags: CNS disorders, biopharmaceutical, clinical-stage, depression, epilepsy, neuroscience, therapies

Symbol: PRAX

Recent Price: $76.26

Industry: Biotechnology

CEO: Mr. Marcio Silva De'Souza M.B.A.

Sector: Healthcare

Employees: 82

Address: 99 High Street, Boston, MA 02110

Phone: 617 300 8460

Last updated: 2024-12-31